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Abstract
Background: Lymph node involvement and tumor-induced lymphangiogenesis appear as the earliest features of
esophageal squamous cell carcinoma (ESCC), although the molecular regulatory mechanisms involved have
remained unclear. Our aim was to investigate the contribution of NF-B and Notch1 signaling to lymph node
involvement and tumor-induced lymphangiogenesis in ESCC.
Material and methods: NF-B and Notch1 expression in 60 tissue samples of ESCC were assessed by
immunohistochemical staining. The correlations of NF-B and Notch1 with lymph node involvement, lymphatic
vessel density (LVD), podoplanin, and vascular endothelial growth factor-C (VEGF-C) were further evaluated to
determine the association of NF-B and Notch1 expression with tumor-induced lymphangiogenesis.
Results: Chi-square tests revealed that NF-B and Notch1 expression in ESCC tissues were significant associated
with lymph node metastasis, LVD, podoplanin, and VEGF-C expression. Strong expression of NF-B, but weak
expression of Notch1, was observed in tumor tissues with lymph nodes involvement (P < 0.05 for both). The mean
histoscores of LVD, podoplanin, and VEGF-C staining were higher in high-NF-B-expressing tissue than in low-
expressing tissue (P < 0.05 for each). In contrast, the mean histoscores of LVD and VEGF-C staining were lower in
high-Notch1-expressing tissue than in low-expressing tissue (P < 0.05 for both). A multiple factors analysis of LVD
and VEGF-C further demonstrated that LVD and VEGF-C status were significantly correlated with NF-B and Notch1
expression in tumors. NF-B and Notch1 expression were also significantly inversely correlated (P < 0.05).
Conclusion: These results suggest that different patterns of NF-B and Notch1 signaling contribute to lymph
nodes metastasis and tumor-induced lymphangiogenesis of ESCC, and reveal that up-regulation of NF-Bi s
associated with down-regulation of Notch1 in tumor tissue.
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Background
Esophageal squamous cell carcinoma (ESCC) is one of
the most aggressive and invasive malignancies in the
world. Despite combined modality approaches, the prog-
nosis in cases of ESCC remains extremely poor; patients
exhibit a low 5-year survival rate, with the majority of
cancer-related deaths resulting from metastatic spread
of tumor cells [1]. Clinical observations have shown that
lymph node involvement appears as one of the earliest
features of ESCC [2]. Some abnormal molecular biology
changes, such as tumor-induced lymphangiogenesis, are
also considered to play a central role in the migration
and metastatic spread of ESCC to lymph nodes. For
example, high expression of vascular endothelial growth
factor (VEGF)-C and the presence of newly developed
lymphatic ducts was found to be the main avenue for
dissemination of malignant cells to lymph nodes in
ESCC [3-5]. Lymphangiogenesis is associated with
neoplastic progression in the esophageal mucosa, and
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epithelium as it progresses through dysplasia to esopha-
geal carcinoma [6]. Moreover, lymphangiogenesis has
been shown to correlate with the depth of malignant
invasion, tumor stage, lymphatic and venous invasion,
and lymph node metastasis in esophageal cancer [7].
However, although several positive and negative regu-
lators, including angiopoietins [8], neuropilin-2 [9], and
COX-2 [10], are believed to contribute to the robust
production of VEGF-C, the molecular regulatory
mechanisms involved in tumor-induced lymphangiogen-
esis of ESCC have remained unclear. One potential can-
didate is nuclear factor-B( N F - B), a sequence-specific
transcription factor that responds to cellular signaling
pathways involved in cell survival and resistance to che-
motherapy; notably, aberrant NF-B activation has been
associated with some malignancies [11-13]. Although
abnormities of NF-B signaling have been reported to
play an important role in carcinogenesis by promoting
tumor-induced angiogenesis and neoplastic proliferation
[14], the association of NF-B with lymphangiogenesis
in ESCC is less clear. Members of the Notch family of
cell surface receptors and their ligands also warrant
attention based on their role in vasculogenesis and their
potential to act as oncogenes in the pathogenesis of cer-
tain carcinomas. These highly conserved proteins regu-
late “decisions” involved in cell-fate determination,
including those involved in mammalian vascular devel-
opment [15]. The finding that genes of the Notch sig-
naling cascade are robustly expressed in the vasculature
suggests that Notch signaling guides endothelial cells
and associated mural cells through the cell-fate deci-
sions needed to form and maintain the vascular system
[16]. Although Notch signaling anomalies are found in
melanoma, non-small cell lung cancer, cervical cancer
and neuroblastoma, consistent with the presumed onco-
genic role of Notch signaling during tumorigenesis, the
finding that Notch signaling is diminished in epithelial
squamous cell carcinoma of the skin would seem to sug-
gest that Notch might serve as a tumor suppressor.
These apparently contradictory functions of Notch sig-
naling strongly indicate that the outcome of Notch acti-
vation is dependent on malignant cellular context [17].
Given the uncertain contributions of differential NF-
B and Notch signaling to tumor-induced lymphangio-
genesis of ESCC, we here assessed the expression of
NF-B and Notch1 in ESCC tissues and evaluated their
association with various clinical characteristics, including
sex, age, lymph node metastasis, tumor-node-metastasis
(TNM) classification, and differentiation (well, moderate,
or poor grade) of tumor cells in ESCC. Lymphangioge-
netic characteristics and their associations with NF-B
and Notch1 signaling were also measured to determine
the contribution of NF-B and Notch signaling to
tumor-induced lymphangiogenesis.
Materials and Methods
Patients and specimens
A total of 60 ESCC tissue samples excised from January
2004 to December 2006 were selected from the Depart-
ment of Thoracic Surgery of the First Affiliated Hospi-
tal, Sun Yat-sen University. All patients were treated by
esophagectomy and did not receive chemotherapy or
radiotherapy before surgery. Clinical information was
obtained through reviews of preoperative and periopera-
tive medical records, or telephone or written correspon-
dence. These cases were classified according to the
Health Organization criteria (TNM system) and staged
appropriately. The study has been approved by the hos-
pital ethical committee and each subject had signed the
written informed consent.
Pathological grading
Paraffin-embedded specimens of each case were col-
lected, and 5-mm thick tissue sections were cut and
fixed onto siliconized slides. The histopathology of each
sample was studied using hematoxylin and eosin (H&E)
staining. The same sections were deparaffinized and
rehydrated with deionized water. Samples were stained
with hematoxylin for 5 min and ablated with 1% hydro-
chloric acid alcohol for 30 s then immersed in distilled
water for 15 min. Slides were stained with 0.5% eosin
for 2 min, then dehydrated, immersed in xylene for 15
min, and mounted. All specimens were evaluated with
respect to histological subtype, differentiation, and
tumor stage according to World Health Organization
criteria. Tumor size and metastatic lymph node number
and locations were obtained from pathology reports.
Immunohistochemical staining
Immunohistochemical staining was carried out using the
streptavidin-peroxidase method. Briefly, each tissue sec-
tion was deparaffinized, rehydrated, and then incubated
with fresh 3% hydrogen peroxide (H2O2)i nm e t h a n o l
for 15 min. After rinsing with phosphate-buffered saline
(PBS), antigen retrieval was carried out by incubating at
100°C for 15 min in 0.01 M sodium citrate buffer (pH
6.0) using a microwave oven. Next, non-specific binding
was blocked by incubating with normal goat serum for
15 min at room temperature, followed by incubation at
4°C overnight with anti-NF-B antibody (sc-8008, 1:500;
S a n t aC r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ,U S A ) ,a n t i -
Notch1 antibody (sc-6014-R, 1:500; Santa Cruz Biotech-
nology), anti-VEGF-C antibody (18-2255, 1:100; Invitro-
gen, Carlsbad, CA, USA), anti-VEGFR-3 antibody
(MAB3757, 1:150; Chemicon, Santa Cruz, CA, USA),
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Chemicon, Santa Cruz, CA, USA). After rinsing with
PBS, slides were incubated for 10 min at room tempera-
ture with biotin-conjugated secondary antibodies, fol-
lowed by incubation with a streptavidin-conjugated
peroxidase working solution for 10 min. Subsequently,
sections were stained for 3-5 min with 3,3’-diaminoben-
zidine tetrahydrochloride (DAB), counterstained with
Mayer’s hematoxylin, dehydrated, and mounted. Nega-
tive controls were prepared by substituting PBS for pri-
mary antibody.
Assessment of immunohistochemical staining
Nuclear staining of NF-B and cytoplasmic staining of
Notch1 and VEGF-C were scored in this study. The
intensity of NF-B, Notch1, podoplanin, and/or VEGF-
C staining was score on a scale of 0-3 as follows: 0,
n e g a t i v e ;1 ,l i g h t ;2 ,m o d e r a t e ;a n d3 ,i n t e n s e .T h ep e r -
centage of positive tumor cells at each intensity level
was presented as a ratio of the percentage of surface
area covered at each intensity score to total tumor cell
area. Areas that were negative were given a value of 0.
We analyzed 10-12 discrete foci in each section and
generated an average stain intensity and percentage of
surface area covered. The final histoscore was calculated
using the formula, histoscore = (1 × percentage of
weakly positive tumor cells) + (2 × percentage of mod-
erately positive tumor cells) + (3 × percentage of inten-
sely positive tumor cells). The histoscore was
determined independently by two investigators by
microscopic examination (magnification, × 400). If the
histoscores determined by the two investigators differed
by more than 15%, a recount was taken to reach an
agreement. NF-B, Notch1, podoplanin, and VEGF-C
expression were classified into high- and low-expressing
groups, using the median value of their respective histo-
scores as a cut-off value.
Evaluation of LVD
Immunohistochemical reactions for VEGFR-3 antigen
were evaluated independently by two investigators using
a microscope. The three most vascularized areas within
a tumor ("hot spots”) were chosen at low magnification
(× 40), and vessels in a representative high-magnifica-
tion (× 400; 0.152 mm
2; 0.44-mm diameter) field in
each of these three areas were counted. The high-mag-
nification fields were then marked for subsequent image
cytometric analysis. Single immunoreactive endothelial
cells or endothelial cell clusters separated from other
micro-lymphatic vessels were counted as individual
micro-lymphatic vessels. Endothelial staining in large
vessels with tunica media and nonspecific staining of
non-endothelial structures were excluded in micro-lym-
phatic vessels counts. The mean visual micro-lymphatic
vessel density of VEFGR-3 staining was calculated as the
average of six counts (two hot spots and three micro-
scopic fields). Micro-lymphatic vessel counts higher
than the median micro-lymphatic vessel count were
taken as high LVD, and those that were lower than the
median were taken as low LVD.
Statistical analysis
All calculations were done using the statistical software
SPSS V.14.0 (Chicago, Illinois, USA). Data were shown
as mean ± standard deviation. Spearman’s coefficient of
correlation, Chi-squared tests, and Mann-Whitney tests
were used as appropriate. A multivariate model using
logistic regression analysis was used to evaluate statisti-
cal associations among variables. For all tests, a two-
sided P-value less than 0.05 was considered to be signifi-
cant. Hazard ratios (HR) and their corresponding 95%
confidence intervals (95% CI) were computed to provide
quantitative information about the relevance of the
results of the statistical analysis.
Results
Basic clinical information and tumor characteristics
Forty-six male and 14 female patients (mean age, 57.6 ±
10.4 years; range, 36-79 years) with ESCC treated by
curative surgical resection were enrolled in the study. Of
the 60 tumors, 15 were well differentiated, 27 were
moderately differentiated, and 18 were poorly differen-
tiated. Using the TNM staging system of the Interna-
tional Union Against Cancer (2009) [18], cases were
classified as stage I (n = 9), stage II (n = 11), and stage
III (n = 40). Twenty-four of 60 patients had lymph node
metastasis, according to surgery and pathology reports.
Patient data were analyzed after a 5-year follow-up;
information was obtained in 91.7% (55 of 60) of cases.
The median overall survival was 26.9 ± 2.7 months (95%
CI: 21.4-31.9 months), and the mean overall survival
was 38.1 ± 6.5 months (95% CI: 27.6-52.0 months). The
clinical characteristics of study samples are summarized
in Table 1.
Association of NF-B and Notch1 expression
with clinical features of ESCC
The association of NF-B expression with several clini-
copathologic factors is shown in Table 1. NF-B expres-
sion in tumor cells was significantly correlated with
lymph node metastasis (c
2 = 32.727, P = 0.001), LVD
(c
2 =4 . 3 1 2 ,P = 0.038), VEGF-C expression (c
2 = 4.241,
P = 0.039), podoplanin expression (c
2 = 8.076, P =
0.004), and Notch1 expression (c
2 = 9.675, P = 0.002).
Similarly, Notch1 expression in tumor cells was signifi-
cantly correlated with lymph nodes metastasis (c
2 =
10.162, P =0 . 0 0 1 ) ,L V D( c
2 =6 . 3 6 2 ,P = 0.010), VEGF-
Ce x p r e s s i o n( c
2 = 17.176, P = 0.001), and podoplanin
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2 =6 . 8 7 7 ,P = 0.008). There were no asso-
ciations of Notch1 or NF-Bw i t ha g e ,s e x ,o rT N M
stage of tumors.
Association of NF-B and Notch1 with lymph node
metastasis in ESCC
In order to observe the association of NF-Ba n d
Notch1 expression levels with lymph nodes metastasis
in greater detail, we compared the histoscores of NF-B
and Notch1 expression in the context of lymph node
involvement (Figure 1). Significantly, our data suggest
differences in the patterns of NF-B and Notch1 signal-
ing with respect to lymph node metastasis status in
ESCC, demonstrating strong expression of NF-Bi n
ESCC tissue, but weak expression of Notch1 with lymph
node involvement (P < 0.05 for both). A multivariate
analysis of lymph node involvement in ESCC (Table 2)
indicated a positive association of NF-Ba n dV E G F - C
expression with lymph node metastasis, independent of
T stage, sex, age, and differentiation of tumor cells.
Association of NF-B and Notch1 with tumor-induced
lymphangiogenesis in ESCC
The average histoscore of LVD (VEGF-R3) distribution, an
important lymphangiogenetic factor, was 5.06 ± 0.28 in all
ESCC samples in our study. LVD histoscores were higher
(5.95 ± 0.35) in NF-B-high patients and lower (4.23 ±
0.39) in NF-B-low patients (Figure 2). Conversely, lower
rates of LVD were observed in Notch1-high patients (3.92
± 0.38), whereas higher rates were found in Notch1-low
patients (6.20 ± 0.31). As another important lymphangio-
genetic factor, the average histoscore of podoplanin distri-
bution was 7.34 ± 0.87 in all ESCC samples in present
study, and their histoscores were also higher (10.08 ± 1.28)
in NF-B-high patients and lower (5.49 ± 1.05) in NF-B-
low patients (p = 0.008). Thus, LVD was significantly posi-
tively associated with NF-B expression, but negatively
associated with Notch1 expression. Consistent with this,
VEGF-C expression was positively correlated with NF-B
and negatively correlated with Notch1 (Figure 3). To
directly link NF-B and Notch1 expression with
Table 1 Association of NF-B and Notch1 expression with clinical characteristics
Clinicopathological feature NF-B expression P-value Notch1 expression P-value
High Low High Low
Gender
Male 21 25 0.451 22 24 0.887
Female 8 6 7 7
Age (years)
≤ 60 17 23 0.201 23 17 0.058
>6 0 1 2 8 6 1 4
Differentiation
Well 7 8 0.231 3 12 0.001
Moderate 16 11 10 17
Poor 6 12 16 2
TNM stages
I + II 8 12 0.361 10 10 0.855
III 21 19 19 21
Lymphatic metastasis
With 23 2 0.001 6 19 0.001
Without 6 29 23 12
LVD (VEGF-R3)
High 19 12 0.038 10 21 0.010
Low 10 19 19 10
Podoplanin
High 20 10 0.004 8 19 0.008
Low 9 21 21 12
VEGF-C expression
High 18 11 0.039 6 23 0.001
Low 11 20 23 8
Notch1 expression
High 8 21 0.002
Low 10 21
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factors analysis of LVD. As shown in Table 3, differ-
ences in LVD status were significantly correlated with
expression of NF-B, Notch1 and VEGF-C, indepen-
dent of T stage, sex, age, and differentiation status of
tumor cells. Moreover, a multiple factors analysis of
VEGF-C, which is a key factor in tumor-induced lym-
phangiogenesis, revealed a positive association of
VEGF-C status in ESCC tissue with the expression of
NF-B and a negative association with the expression
o fN o t c h 1 ,i n d e p e n d e n to fTs t a g e ,s e x ,a g e ,a n dt u m o r
cell differentiation status (Table 4).
Association of NF-B expression with Notch1 expression
in ESCC
Collectively, our data suggested a significant correla-
tion between NF-B and Notch1 expression in ESCC
tissues (Pearson coefficient, 0.798; P = 0.001; Spear-
man coefficient, -0.723; P =0 . 0 0 1 ;F i g u r e4 A ) .L o w e r
NF-B histoscores were observed in Notch1-high
patients (3.52 ± 0.53), whereas higher NF-Bh i s t o -
scores were found in Notch1-low patients (6.71 ±
0.74; Figure 4B). These results indicate that up-regu-
lation of NF-B is associated with down-regulation
of Notch1 in ESCC.
Discussion
Esophageal cancer is a disease with poor prognosis. Of
t h em a n yp r o g n o s t i cf a c t o r si dentified to date, lymph
node metastasis is one of the most significant, and
tumor-associated lymphangiogenesis is believed to be a
crucial prognostic factor for patient outcome [19,20].
VEGF-C has been characterized as a lymphangiogenic
growth factor and has been shown to signal through the
receptor, VEGFR-3 [21]. Moreover, there is a positive
relationship between the expression of VEGF-C and the
prognosis of patients with ESCC [20]. However, the pre-
cise mechanisms that underlie the development of
Figure 1 Association of NF-B and Notch1 expression with lymph node metastasis in ESCC. (A) Compared with samples of ESCC without
lymph node involvement, the samples of ESCC with lymph node involvement showed high levels of NF-B expression and low levels of Notch1
expression (magnification, ×200). (B) In ESCC tissue with lymph node involvement, NF-B staining was strong (mean histoscore, 5.55 ± 0.41) and
Notch1 staining was weak (mean histoscore, 3.41 ± 0.36) compared with tissues without lymph node involvement (mean histoscores, 4.90 ± 0.43
and 4.27 ± 0.27 for NF-B and Notch1, respectively; P < 0.05 for both).
Table 2 Multivariate analysis of lymph node involvement
in ESCC (logistic regression model)
Variable b HR (95% CI) P
NF-B 1.551 4.716 (1.037-21.454) 0.045
Notch1 -0.273 0.761 (0.459-1.263) 0.291
VEGF-C 0.866 2.377 (1.257-4.494) 0.008
T stage 0.117 1.125 (0.627-2.016) 0.694
Sex -0.157 0.855 (0.160-4.566) 0.854
Age 0.030 1.030 (0.966-1.098) 0.365
Differentiation - 0.126 0.882 (0.284-2.736) 0.828
Abbreviations: HR, hazard ratio; CI, confidence interval of the estimated HR.
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from clear.
Recent accumulating evidence suggests that the NF-B
signaling pathway plays a critical role in carcinogenesis,
protection from apoptosis, and chemoresistance in a
number of cancer types, including head and neck can-
cer, breast cancer, and esophageal carcinoma [22-24].
NF-B, which is retained in the cytoplasm through asso-
ciation with IBa, is liberated upon phosphorylation of
IBa, whereupon it enters the nucleus to regulate the
expression of genes involved in cell apoptosis and prolif-
eration [25]. Importantly, NF-B appears to be one of
the main molecular mechanisms responsible for tumor
formation and progression [26]. NF-B is reported to be
associated with invasive angiogenesis in cancer [27], and
lymphatic endothelial cells express a set of specific mar-
kers (e.g., VEGF-C and VEGFR-3) [28]. On the basis of
these observations, we assessed the relationships
between intratumoral NF-Ba n dV E G F R - 3o rV E G F - C
expression in ESCC, in an effort to demonstrate the
association of NF-B with tumor-induced lymphangio-
genesis. Our demonstration of a positive link between
high levels of NF-B expression and LVD and VEGF-C
suggests that NF-B may contribute to tumor-associated
lymphangiogenesis in ESCC. The mechanistic aspect of
the linkage between NF-B and LVD was supported by
the report that activation of NF-B followed by sequen-
tial up-regulation of VEGFR-3 expression in cultured
lymphatic endothelial cells and increasing of prolifera-
tion and migration, it suggested that induction of NF-
Figure 2 Association of NF-B and Notch1 expression with lymphangiogenesis in ESCC. (A) NF-B expression in ESCC tissue was positively
correlated with LVD in tumors. (B) Notch1 expression in ESCC tissue was negatively correlated with LVD in tumors. (C) The mean histoscore of
LVD expression was higher in ESCC tissue with high levels of NF-B expression (5.95 ± 0.35) than in those with low levels of NF-B expression
(4.22 ± 0.39; P < 0.05). Conversely, the mean LVD histoscore (VEGFR-3 expression) was lower in ESCC tissue with high levels of Notch1 expression
(3.92 ± 0.38) than in those with low levels of Notch1 expression (6.20 ± 0.31; P < 0.05).
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Page 6 of 9Figure 3 Association of NF-B and Notch1 expression with VEGF-C in ESCC. (A) NF-B expression in ESCC tissue was positively correlated
with VEGF-C expression in tumors. (B) Notch1 expression in ESCC tissue was negatively correlated with VEGF-C expression in tumors. (C) The
mean histoscore of VEGF-C expression was higher in ESCC tissue with high levels of NF-B expression (6.48 ± 0.44) than in those with low levels
of NF-B expression (3.53 ± 0.39; P < 0.05). Conversely, the mean histoscore of VEGF-C expression was lower in ESCC tissue with high levels of
Notch1 expression (3.41 ± 0.37) than in those with low levels of Notch1 expression (6.51 ± 0.84; P < 0.05).
Table 3 Multivariate analysis of LVD (VEGF-R3) in ESCC
(logistic regression model)
Variable b HR (95% CI) P
NF-B 1.659 5.255 (1.296-21.300) 0.020
Notch1 -0.607 0.545 (0.329-0.904) 0.019
VEGF-C 0.583 1.791 (1.021-3.144) 0.042
T stage -0.353 0.793 (0.442-1.118) 0.136
Sex -1.548 0.213 (0.035-1.285) 0.092
Age 0.411 1.509 (0.092-24.751) 0.773
Differentiation 1.659 0.509 (0.099-2.627) 0.420
Abbreviations: HR, hazard ratio; CI, confidence interval of the estimated HR.
Table 4 Multivariate analysis of VEGF-C in ESCC (logistic
regression model)
Variable b HR (95% CI) P
NF-B 1.930 6.889 (1.269-37.394) 0.025
Notch1 -0.605 0.546 (0.331-0.902) 0.018
T stage 0.765 2.149 (0.593-7.783) 0.244
Sex 0.371 1.450 (0.846-2.484) 0.176
Age 0.026 1.026 (0.969-1.088) 0.376
Differentiation 0.511 1.667 (0.607-4.580) 0.321
Abbreviations: HR, hazard ratio; CI, confidence interval of the estimated HR.
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tic endothelium to VEGFR-3 binding factors and
resulted in lymphangiogenesis [29]. Interestingly, LVD
reduced prominently in lungs of mice lacking p50 subu-
nit of NF-B, which demonstrated the important role of
p50 subunit of NF-B in regulating the expression of
VEGFR-3 [30]. Regarding to the above molecular chan-
ging were found in inflammation-induced lymphangio-
genesis, further research will be required to confirm the
mechanistic aspect between NF-Ba n dL V Di nt u m o r -
associated lymphangiogenesis.
In contrast, we found that the expression of Notch1,
which is involved in regulating vascular development,
was negatively correlated with the lymphatic markers,
VEGFR-3 and VEGF-C. These findings seemingly
contradict those of a previous study, which reported
that Notch signaling is positively correlated with
VEGFR-3 and other lymphatic endothelial cell markers
in physiological lymphangiogenesis [31]. The role of
Notch1 in various tumors has been obscure, although
researchers have suggested that Notch1 might contri-
bute to guiding endothelial cells through the cell fate
decisions needed to form and maintain a functional vas-
cular network [32]; consistent with such a role, multiple
connections between the VEGF system and the Notch
signaling cascade have been previously described [33].
In a malignant environment, such as invasive breast car-
cinoma, cleaved (activated) Notch1 has been observed in
a subset of lymphatic endothelial nuclei, indicating that
Notch1 is not only expressed but is activated in tumor
lymphatic vessels [31]. However, how Notch signaling
participates in pathological tumor lymphangiogenesis
remains unclear. Our finding that Notch1 expression is
negatively associated with high expression of VEGF-C
and VEGFR-3 in ESCC may indicate that down-regula-
tion of Notch1 signaling contributes to tumor-induced
lymphangiogenesis.
Conclusions
Our findings demonstrate that high NF-Ba n dl o w
Notch1 expression are correlated with high expression
of VEGFR-3 (a marker of LVD) and VEGF-C, in ESCC
patients, revealing an inverse relationship between
Notch1 and NF-B signaling and tumor-induced lym-
phangiogenesis. Taken together, our findings imply that
Notch1 and NF-B signaling have counter-acting roles
in tumor-induced lymphangiogenesis in ESCC, and sug-
gest that Notch may differentially regulate physiological
and tumor-induced lymphangiogenesis.
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